



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Yaron Ilan et al.

Serial No. 10/676,045

Filed: September 30, 2003

Title: EDUCATED NKT CELLS AND THEIR USES  
IN THE TREATMENT OF IMMUNE-RELATED  
DISEASES

Group Art Unit: 1644

Examiner: Zachary Skelding

527 Madison Avenue, 9<sup>th</sup> Floor  
New York, NY 10022-4304  
December 21, 2006


**FILED VIA EXPRESS MAIL**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT OF JUNE 21, 2006**

Dear Sirs:

In the Office Action of June 21, 2006, the Examiner requested restriction under 35 U.S.C. § 121 to one of Groups I-VIII, which are purportedly distinct inventions. Applicants hereby

EXPRESS MAIL CERTIFICATE	
"Express Mail" Label No.	<u>EV655205455US</u>
Deposit Date	<u>December 21, 2006</u>
I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents and Trademarks, P.O. Box 1450, Alexandria, Virginia 22313-1450.	
 Natalie Bogdanos Reg. No. 52,480	<u>12/21/06</u> Date

provisionally elect Group II, which covers claims 3, 5-15, 19, 24 and 32, drawn to a method of treatment using NKT cells as an anti-inflammatory, classified in Class 424, subclass 93.21, according to the Office Action, with traverse. Applicants hereby provisionally elect Autoimmune Liver Disease as the specific immune-related or immune-mediated disorder, with traverse. Applicants also hereby provisionally elect antigens or epitopes as the set of culture conditions with traverse, and also elect “allogenic antigens obtained from donors suffering from said immune-related or immune-mediated disease”, with traverse. Applicants moreover reserve the right to file divisional applications directed to non-elected subject matter.